Compare Abeona Therapeutics Inc (ABEO) vs Weibo Corp (WB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Weibo Corp — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Weibo Corp trades at $7.6 (market cap $1.85B). The key difference: Weibo Corp is far larger — about 5× Abeona Therapeutics Inc's market cap, and Weibo Corp pays a 8.16% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WB | |
|---|---|---|
Market Cap | $373.32M | $1.85B |
Sector | Health | Media |
52-Week High | $7.23 | $12.83 |
52-Week Low | $4.17 | $7.20 |
Enterprise Value | $228.22M | $1.12B |
Dividend Yield | — | 8.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Weibo (WB) trades at $7.47, up 1.49% today, with a bullish technical signal and strong fundamentals including a 25.55% net margin and 10.33% ROE. Recent quarterly earnings missed expectations, but the company maintains robust cash flow and a high dividend yield. Valuation metrics appear attractive with a P/E of 5.29 and P/B of 0.48, while analyst sentiment is mixed with 45% buy ratings.
The outlook balances deep value against competitive pressures. The stock offers significant upside if monetization improves, but faces risks from user engagement declines and rivalry with Douyin. Near-term catalysts include Q2 2026 earnings and dividend payments, though consistent EPS misses warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
